Expert consensus on the perioperative management of gene therapy for inherited retinal diseases in China

Title: Expert consensus on the perioperative management of gene therapy for inherited retinal diseases in China
Edition: Original
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users:
Evidence classification method: Not Applicable
Development unit: 中华医学会眼科学分会眼底病学组 中国医师协会眼科医师分会眼底病专业委员会
Registration time: 2022-06-18
Registration number: IPGRP-2022CN348
Purpose of the guideline: Inherited retinal diseases (IRDs) are a group of severe retinal degenerative diseases leading to permanent visual impairment. IRDs are the major cause of irreversible blindness in children and working age groups. Gene therapy is a new clinical treatment method and currently the only clear and effective treatment for IRDs. while, there are still risks in clinical research and application. How to standardize perioperative management and reduce the potential risks of treatment is one of the keys to ensure the safety and effectiveness of treatment. However, there is no systematic and standardized guidance on the perioperative management for IRDs gene therapy. Therefore, in order to standardize the perioperative management, the Fundus Disease Group of Ophthalmology Society of Chinese Medical Association and Chinese Medical Doctor Association organized domestic experts to put forward standardized opinions on the perioperative management of IRDs gene therapy in China after repeated discussion and combined with domestic and foreign research experience, so as to provide clinicians with reference and application in clinical research and practice.